ACE inhibitors SHOULD be given-unless contraindicated-within the first day of admission and continued indefinitely for NSTE ACS patients with: 1.
ACE inhibitors MAY be given-unless contraindicated--during the course of hospitalization and continued indefinitely for ALL the other patients with NSTE ACS.
She presented the findings of the OASIS (Organization to Assess Strategies in Acute Ischemic Syndromes) 5 Women's Substudy, involving 184 women with NSTE
ACS, 80% of whom had elevated cardiac damage biomarkers.
In a NSTE
class, high-level learners can overcome misunderstanding arising from cultural differences between them and the teacher through communication.
Harrington described patients with NSTE
ACS who are managed solely medically as "almost a forgotten population.
We analyzed systematically the pre-PCI cTn trends in 10 199 NSTE
ACS patients who underwent PCI during the index hospitalization in EARLY ACS and SYNERGY trials, in which cTn and CK-MB were collected serially (9).
Use of Evidence-Based Medications in NSTE
ACS Patients Medically managed CABG-managed PCI-managed patients patients patients Clopidogrel 45% 32% 95% ACE inhibitor or ARB 65% 55% 67% Lipid-lowering drug 81% 87% 94% [beta]-Blocker 91% 93% 94% Aspirin 90% 97% 98% Note: Based on 2005 data from 138,714 patients in the CRUSADE study.
4] Nonstandard abbreviations: IL, interleukin; CV, cardiovascular, Th2, T- helper type 2; HF, heart failure; MI, myocardial infarction; STEMI, ST-elevation MI; NSTE
, non-ST-elevation; ACS, acute coronary syndrome; MERLIN-TIMI 36, Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36; BNP, B-type natriuretic peptide; CVD, cardiovascular death; cTnI, cardiac troponin I; HR, hazard ratio; MPO, myeloperoxidase; hsCRP, high-sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; NRI, net reclassification improvement; IDI, integrated discrimination improvement; ST2L, ST2 membrane-bound isoform; sST2, ST2 soluble isoform.
2003 (7) 1458 PTCA/Stent (43%) (22% NSTE
ACS) Dibra et al.
We evaluated this assay for the assessment of the short-term risk of death and recurrent ischemic events among patients with suspected NSTE
ACS enrolled in the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS)-Thrombolysis in Myocardial Infarction (TIMI) 16 trial.